Under this partnership, Cipla Medpro will market Actavis’ product portfolio, inclusive of products in the MCC pipeline.
The partnership leverages the commercial strength of Cipla Medpro in South Africa together with the strong global product pipeline of Teva. It spans across a number of therapeutic areas such as oncology, cardiovascular, CNS, and over-the-counter products.
Paul Miller, CEO of Cipla sub-Saharan Africa, says:“We are very pleased with the addition of these new products, including strong brands like Accurate, Lokit, Amoclan and Sudocrem. Cipla’s strategy is to grow through such alliances. Ultimately, patients benefit with better reach of quality medicines.”
Erez Israeli, president and CEO of Teva growth markets, notes that: “The partnership with Cipla Medpro SA allows us to reach millions of patients in South Africa, providing them with increased access to healthcare.”
